The past decade has witnessed an enormous increase in our knowledge of the variety and
complexity of neuropathological and neurochemical changes in Alzheimer's disease …

After reviewing the evidence for cholinergic pathology in Alzheimer's disease and related
disorders, this paper reviews strategies for treating dementia using cholinomimetic drugs …

Nicotine in patients with dementia of the Alzheimer type (DAT) producted a significant and
marked improvement in discriminative sensitivity and reaction times on a computerised test …

The authors discuss the cholinergic hypothesis of geriatric memory dysfunction, which
proposes the following:(1) Significant, functional disturbances in cholinergic activity occur in …

In Alzheimer's disease (AD), there is a loss of presynaptic cholinergic markers in the
cerebral cortex, but the nature of cholinergic receptor changes is unclear. In this study,[3 …

The following receptors were assessed post-mortem in the hippocampi (anterior region) of
eight patients with Alzheimer's disease and nine age-matched controls, using …

• Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy are all
characterized by loss of neurons in the basal forebrain cholinergic system and by associated …

Cholinergic receptors (muscarinic subtypes M1 and M2, and putative nicotinic binding) have
been examined in the hippocampus obtained at autopsy from a variety of patients with …

The total population of muscarinic receptors and a subpopulation of muscarinic receptors
with high affinity for agonists were measured with [3 H] quinuclidinyl benzilate and [3 H] …

The effects of two doses of muscarinic (arecoline and scopolamine) and nicotinic (nicotine
and mecamylamine) cholinergic receptor agonists and antagonists on the radial maze errors …